Digoxin Revisited: An Updated Review in the Light of Recent Trials
5 affiliations
- 1Department of Internal Medicine, The Jewish Hospital of Cincinnati, Cincinnati, OH, USA
- 2Department of Internal Medicine, FMH College of Medicine and Dentistry, Lahore, Punjab, Pakistan
- 3Department of Geriatric Medicine, NYU Langone Health, New York, NY, USA
- 4Department of Cardiology, Rochester Regional Health, Rochester, NY, USA
- 5Mercy Heart Institute, Cincinnati, OH, USA
Abstract
Isolated from Digitalis species following William Withering’s 1785 work on foxglove, digoxin inhibits myocardial Na+/K+-ATPase, raising intracellular calcium and vagal tone to produce inotropic, rate-controlling, and neurohormonal-deactivating effects. The foundational DIG trial (1997) showed no mortality benefit but reduced heart failure hospitalizations, prompting a progressive guideline downgrade. Three decades later, DIGIT-HF (2025, digitoxin) and DECISION (2026, low dose digoxin) retested cardiac glycosides atop modern four pillar guideline-directed medical therapy (GDMT). DIGIT-HF significantly reduced the composite of death or worsening heart failure (hazard ratio (HR), 0.82), while DECISION showed a numerical but nonsignificant benefit. A pooled meta-analysis of DIG, DIGIT-HF, and DECISION (9,013 patients) confirmed a consistent 15% reduction in worsening heart failure events across three decades of changing background therapy, without a significant mortality effect. The Dig-RHD trial addressed an unstudied population: symptomatic rheumatic heart disease (RHD), a chronic valvular heart disease that results from permanent damage to cardiac valves due to group A streptococcal infection. RHD affects roughly 40 million people and causes approximately 300,000 deaths annually, disproportionately in low- and middle-income countries. In 1,769 patients randomized across 12 Indian centers, digoxin significantly reduced the composite of death or new-onset/worsening heart failure (31.4% vs. 35.5%; HR, 0.82; 95% confidence interval (CI), 0.70 to 0.97; P = 0.02), with greater benefit in atrial fibrillation, women, and patients with low body mass index (BMI), and a number needed to treat of approximately 14 over 2 years. Digoxin is not a mortality-reducing drug, but pooled contemporary evidence establishes it as a reproducible, low-cost tool for reducing heart failure events, now supported for the first time by high-quality randomized data in RHD, a population with substantial global burden and no prior evidence-based medical therapy. These findings warrant reconsideration of digoxin’s guideline status and development of RHD-specific recommendations.
Related
- Aspirin-Based Thromboprophylaxis Versus Anticoagulant Regimens After Total Hip or Knee Arthroplasty: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
- The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials
- Evaluating selected gene therapies for cardiovascular diseases: an updated scoping review and evidence map of randomised controlled trials
- Comparative Effectiveness of Aquatic Versus Land-Based Exercise on Pain, Physical Function, and Quality of Life in People with Knee Osteoarthritis: An Updated Systematic Review of Randomised Controlled Trials.
- The effects of oral magnesium supplements on vascular and endothelial function: an updated systematic review and meta-analysis of randomized controlled trials
BibTeX
@article{saad2026digoxin,
title = {{Digoxin Revisited: An Updated Review in the Light of Recent Trials}},
author = {Muhammad Saad and Muhammad Abdullah and Ankit Yelamarthy and Krystal John and Abbas Hayat Mallick and Behram Khan and Hassan Tahir and Rajan Krishnamani},
journal = {Cardiology research},
year = {2026},
month = oct,
doi = {10.14740/cr2287},
url = {https://europepmc.org/article/PMC/PMC13719635},
note = {CC BY},
}
RIS
TY - JOUR
TI - Digoxin Revisited: An Updated Review in the Light of Recent Trials
AU - Muhammad Saad
AU - Muhammad Abdullah
AU - Ankit Yelamarthy
AU - Krystal John
AU - Abbas Hayat Mallick
AU - Behram Khan
AU - Hassan Tahir
AU - Rajan Krishnamani
PY - 2026
DA - 2026/10/24
JO - Cardiology research
DO - 10.14740/cr2287
UR - https://europepmc.org/article/PMC/PMC13719635
AB - Isolated from Digitalis species following William Withering’s 1785 work on foxglove, digoxin inhibits myocardial Na+/K+-ATPase, raising intracellular calcium and vagal tone to produce inotropic, rate-controlling, and neurohormonal-deactivating effects. The foundational DIG trial (1997) showed no mortality benefit but reduced heart failure hospitalizations, prompting a progressive guideline downgrade. Three decades later, DIGIT-HF (2025, digitoxin) and DECISION (2026, low dose digoxin) retested cardiac glycosides atop modern four pillar guideline-directed medical therapy (GDMT). DIGIT-HF significantly reduced the composite of death or worsening heart failure (hazard ratio (HR), 0.82), while DECISION showed a numerical but nonsignificant benefit. A pooled meta-analysis of DIG, DIGIT-HF, and DECISION (9,013 patients) confirmed a consistent 15% reduction in worsening heart failure events across three decades of changing background therapy, without a significant mortality effect. The Dig-RHD trial addressed an unstudied population: symptomatic rheumatic heart disease (RHD), a chronic valvular heart disease that results from permanent damage to cardiac valves due to group A streptococcal infection. RHD affects roughly 40 million people and causes approximately 300,000 deaths annually, disproportionately in low- and middle-income countries. In 1,769 patients randomized across 12 Indian centers, digoxin significantly reduced the composite of death or new-onset/worsening heart failure (31.4% vs. 35.5%; HR, 0.82; 95% confidence interval (CI), 0.70 to 0.97; P = 0.02), with greater benefit in atrial fibrillation, women, and patients with low body mass index (BMI), and a number needed to treat of approximately 14 over 2 years. Digoxin is not a mortality-reducing drug, but pooled contemporary evidence establishes it as a reproducible, low-cost tool for reducing heart failure events, now supported for the first time by high-quality randomized data in RHD, a population with substantial global burden and no prior evidence-based medical therapy. These findings warrant reconsideration of digoxin’s guideline status and development of RHD-specific recommendations.
SN - 1923-2829
SN - 1923-2837
ER -